It was found that tumors from systemic sclerosis patients concurrently diagnosed with cancer, carry mutations in the polymerase III polypeptide A (POLR3A) gene, and the presence of certain anti-nuclear antibodies (anti-Scl70, anti PM/Scl-100, anti RNA Polymerase III) in systemic sclerosis patients increases the risk of cancer (121). This evidence concerns the gene POLR3A and systemic sclerosis.